학술논문
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Document Type
Artikel
Author
Source
Annals of the rheumatic diseases. 76(1):96-104
Subject
Language
English
English
English
ISSN
1468-2060